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Poster Session I S259(day -13 to -11), and antithymocyte globulin (rabbit) 7.5 mg/kg(day
-3 to -1). The infused cell dose was 10.71  107/kg nucleated cells
(range from 6.5 to 17 107/kg nucleated cells. Age range from 1.5
year to 7 year. Weight range from10.5 t0 17 kg.
Failure of engraftment is a frequent complication following unre-
lated Umbilical Cord haematopoietic stem cell transplantation for
patients with thalassemia because of Limited dose of stem cells,
multiple transfusions and hypercellular marrow. We tried second
transplant with two unrelated cord blood units for primary graft fail-
ure after cord blood transplantation in one patient. The retransplant
recipients were preconditioned with i.v Cy 120 mg/kg (day -3 to -2) .
Results:Two patients engrafted promptly with 100% donor chime-
rism out of 6 children (33.33%). One child has 50 % donor chime-
rism on day 15. The absolute neutrophil count first exceeded 0.5 
109/l on day 17, and the patient became red cell- and platelet-
independent on days 34 and 49, respectively. All patients engrafted
at a median of 17 days (range 12–19). One patient is transfusion
free for 32 months while second patient is transfusion free for 13
months. There is no transplant related mortality (TRM).
The post transplant complications were mild hepatic veno-
occlusive disease, acute GVHD grade II, and CMV interstitial
pneumonia. The chronic GVHD was limited and could be con-
trolled by Methylprednisolone combined with Mycophenolate.
Conclusions: As there is no marrow donor registry in India, Umbil-
ical cord blood transplantation is a good alternative and is possible. It
should be considered for patients with beta-thalassemia major who
lack traditional bone marrow donors. Transplant should be done af-
ter 18months of age as earliest. Dose of stem cells is the most impor-
tant factor for engraftment. Results can be improved further with
more experience.288
ROLE OF GASTROINTESTINAL ENDOSCOPY IN ALTERING THE
MANAGEMENT OF GASTROINTESTINAL GVHD IN CHILDREN AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Ali, M.1, Asim, M.1, Ling, S.2, Schechter, T.1, Doyle, J.1, Gassas, A.1
1The Hospital for Sick Children, Toronto, ON, Canada; 2The Hospital
for Sick Children, Toronto, ON, Canada
Diagnostic endoscopic procedures are considered part of theman-
agement of children post haematopoietic stem cell transplant
(HSCT) when there is a clinical suspision of gastrointestinal (GI)
acute graft-versus-host disease (aGvHD). However, GI endoscopy
and biopsy in children is invasive, usually performed in main operat-
ing room under general anesthesia with the need for blood product
support in newly engrafted fragile patients. The diagnosis of GI
aGVHD is mostly made on clinical criteria based on stool volume,
ileus and bleeding. Our objective in this study was to review the ben-
efits of GI endoscopies and biopsies in the management of GI
aGVHD in children post HSCT.
From January 2000 to December 2009, 450 children underwent
allogeneic HSCT at the hospital for Sick Children in Toronto. Se-
venty-nine (17.5%) patient underwent endoscopy and GI biopsy
for suspicion of GI aGVHD. The majority were boys, . 10 years
of age with underlying haematological malignancies. Donor sources
were: Unrelated 50; related 29. Stem cell source were; BM60%, cord
25% and PBSC 15%. Themajority received meyloablative regimens
with cyclosporine and methotrexate (or methylprednisolone for
cords) for GvHD prophylaxis. All the patients engrafted within 8-
49 days. Clinical grading of GI aGVHD was, I in 5 patients, II in
39, III in 23 and grade IV in 12 patients. All patients tolerated endos-
copy and GI biopsy well except for one patient who developed duo-
denal hematoma requiring prolonged GI rest.
GI biopsy confirmed aGVHD in 49 (62%) patients and results
were negative in 30(38%) patients. Eight patients had positive viral
studies from the biopsy (adeno 5, CMV 1, HHV6 1 and EBV 1)
and one biopsy was positive for Candida. Thirty- two (40%) patients
have started treatment for GI aGvHD before the biopsy was done
based on clinical criteria, while 24/79 (30%) patients started treat-
ment after the biopsy results. Fifteen (19%) patients required 2nd
line therapy for progressive GI GvHD based on clinical non re-
sponse criteria. Twenty-nine (36%) patients died; 20 due to TRM
and GvHD complications and 9 children died because of recurrence
of their underlying malignancy.Conclusion: GI biopsy results after clinical suspicion of aGvHD in
children post allogeneic HSCT led to starting or altering therapy in
30% of the patients. Patients who were already on therapy for GI
GvHD, biopsy results did not alter their management and escalating
therapy was based on clinical progression.289
MYELO-ABLATIVE EXPOSURE OF BUSULFAN+FLUDARABINE IN
PEDIATRIC HSCT IS A SIMILARLY EFFECTIVE CONDITIONING REGIMEN
COMPARED TO BUCY4 BUT LESS TOXIC
Bartelink, I.H.1, Flinsenberg, T.W.H.2, Bierings, M.2, Egberts, T.1,
Boelens, J.J.2 1UMC Utrecht, Utrecht, Netherlands; 2UMC Utrecht,
Utrecht, Netherlands
Background: Busulfan (Bu) as myeloablative agent is used in condi-
tioning prior to HSCT mainly in combination with cyclophospho-
mide (Cy). In pediatric patients receiving BuCy4, we recently
found a clear association between busulfan-exposure and outcomes:
overall survival (OS) and event free survival (EFS). Toxicity leading
to morbidity and associated mortality remains a limiting factor in
HSCT. Comparative studies in adults showed a favorable toxicity
profile for busulfan+fludarabine (BuFlud) compared to BuCy. In
paediatrics, limited data is available regarding this regimen. BuFlud
was recently (2009) introduced in our center to replace the BuCy4
regimen for myeloid malignancies and all non-malignant indica-
tions. We compared the outcomes with our BuCy4 historic controls
transplanted between 2005-March 2009.
Methods: Fludarabine 40mg/m2 was given in 1 hour prior to a 3
hour infusion of once daily busulfan. Busulfan dose targeting, based
on therapeutic drug monitoring was performed before the second
dose. The target area under the curve (AUC) for Bu was . 74
mg*h/L (cummulative) in both groups Thymoglobuline 10mg/kg
was given in the unrelated donor setting. Primary endpoints were
EFS and OS. Secondary endpoints: acute graft-versus-host disease
(aGvHD), VOD, duration of the neutropenic period and the number
of erythrocyte and thrombocyte transfusions. A risk factor analysis
was performed using univariable and multivariable COX regression.
Results: 29 patients (19 unrelated cord blood, 8 MSD and 2 MUD)
were included in the BuFlud group (median follow up 219 days;
range 42-593) and 44 in the BuCy4 group (975 days; range 6-
1950). The groups were comparable regarding donor source, age,
gender, indication for HSCT and match-grade. EFS and OS in Bu-
Flud and BuCy was 75% vs 71% (NS) and 82% vs. 73% (NS), resp.
Probablility on neutrophile engraftment (day60) was 92% (BuCy4)
and 94% (BuFlu) No difference in aGvHD ($ grade 2) was found,
23%: BuFlu vs 30%: BuCy4. Less VODwas seen in the BuFlu group
(3% vs 18%: p5 0.012). The duration of neutropenia wasmedian 12
days in the BuFlud group compared to 20.5 days in BuCy4 (p 5
0.012). The median number of erythrocyte transfusion in BuFlu
was 1 (range 1-13) vs. 5 (0-22) in BuCy4 (p5 0.04) and thrombocyte
infusions 4 (range 0-33) vs 10 (range 2-44: p 5 0,02), resp.
Conclusions: Busulfan+fludarabine showed to be as effective but
a lesser toxic regimen than BuCy4. Further follow up and extension
of the series is needed.290
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
FOR PEDIATRIC ACUTE MYELOGENOUS LEUKEMIA (AML): MATCHED
SIBLING VS UNRELATED CORD BLOOD (UCB) DONOR
Choudhury, N.G., Duerst, R.E., Chaudhury, S., Tse, W.,
Schneiderman, J., Kletzel, M. Children’s Memorial Hospital, Chicago, IL
Indications for allogeneic HSCT in treatment of pediatric AML
have varied with changing efficacy of conventional AML regimens,
improved understanding of ‘‘high-risk’’ biology, as determined by
minimal residual disease and/or cytogenetic alterations in the leuke-
mic clone and progenitor cell sources. We report the experience of
40 children/young adult patients (pts) with primary AML undergo-
ing initial allogeneic HSCT at Children’s Memorial Hospital be-
tween January 2000 and December 2008 comparing the results of
the UCB recipients (n 5 22) with recipients of matched sibling
(msib) marrow/peripheral blood stem cells (m/PBSC, n 5 18).
S260 Poster Session IThere were 22 males, 18 females, ages 7 mo – 18.7 yrs, median 5.5
years. Stem cell sources for the msibs were marrow for 7 and PBSC
for 11. Conditioning regimen was fTBI based in 25, busulfan based
in 15–of those, 5 were reduced intensity. Graft-versus-host disease
prophylaxis included cyclosporin A and either methotrexate (n 5
35) or mycophenolate (n 5 5). Disease status at time of HSCT
was CR1 in 23, 11 were in CR2 and 6 had evidence of residual
AML (5% by morphology or [+] cytogenetics).
The median time to reach an ANC. 500/ml was 18 days (29 days
for UCB vs 12 after m/PBSC). An unsupported Plt Ct . 20,000/ml
was achieved in 36 pts at a median of 21 days (49 for UCB vs 13 after
m/PBSC). 4 UCB pts failed to engraft with donor hematopoiesis. 14
pts developed Gr II-IV acute GVHD, 8 of the 35 pts surviving more
than 100 days developed chronic GVHD (2 limited, 6 extensive). 9
UCB and 5 m/PBSC pts developed acute GVHD. 7 m/PBSC pa-
tients but only 1 UCB patient developed chronic GVHD.
Overall survival (OS) rates 3 years post HSCT were similar when
comparing UCB recipients (63%) versus combined matched m/
PBSC donors (78%), respectively. This result is despite the higher
proportion of CR2 and PR patients in the UCB cohort (64 vs
17%). OS of patients in CR1 and CR2 at the time of HSCT are
87 % and 43 % respectively.
Table 1. HSCT for Pediatric AML-msib v UCB
All pts, Matched UCB,
n540 sibs, n518 n522Male–Female 22–18 12–6 10–12
Age (yrs, median +/2 sd) 5.5 +/2 5.6 11.6 +/2 5.7 3.5 +/2 4.2
Weight (kg, median) 21 38 15
Diagnosis to HSCT (mo, median) 5.1 3.5 6.4
CR1 23 15 8
CR2 or PR 17 3 14fTBI-VP-CY 25 8 17
Bu4-CY+/2VP 10 6 4
Flu-Bu2 +/2 ATG 5 4 1ANC engraft (days, median) 18 12 29
Platelet engraft (days, median) 21 13 49
Non-engraft 4 4
TRM 5 1 4
Relapse 8 4 4
Overall Survival (%) 69 78 63Our experience supports continued consideration of allogeneic
HSCT for pediatric AML in CR1 utilizing matched sibling donors.
The results using unrelated UCB stem cell sources suggest that
young AML patients lacking a msib donor should search for an
UCB match and consider that option for HSCT in CR1. Methods
to enhance engraftment/limit rejection of UCB could potentially
further improve the results using UCB stem cells.291
HIGH DOSE CARBOPLATIN, ETOPOSIDE, MELPHALAN AND AUTOLO-
GOUS HEMATOPOIETIC STEM CELL RESCUE WITH FOR THE TREATMENT
OF RELAPSED PEDIATRIC GERM CELL TUMORS
Villela, N.C., Gouveia, R.V., Macedo, C.R.D.P., Zecchin, V.G.,
Ginani, V.C., Marconcini, J.F., Felix, O.M.O., Barros, D.P.,
Alves, L.R., Ibanez, A., Simoes, P.C., Silva, A.G., Petrilli, A.S.,
Seber, A. Instituto de Oncologia Pediatrica, S~ao Paulo, SP, Brazil
High dose chemotherapy with autologous hematopoietic stem cell
transplantation (HSCT) is the treatment of choice for relapsed or re-
fractory germ cell tumors (GCT) but few pediatric patients are in-
cluded in most reports. Our objective is to describe the
institutional experience with autologous HSCT for GCT.
Results: From November, 2001 to October, 2010, 11 patients with
GCT underwent HSCT after conditioning therapy with carboplatin
(425 mg/m2/day x 4 days), etoposide (337.5 mg/m2/day x 4 days) and
melphalan (70 mg/m2/day x 2 days) - doses for children older than 2
years of age and with normal renal function. Their median age was
12.5 years (2-19)and seven were female. One had primary centralnervous system (CNS) tumor, 6 gonadal and 4 extra-gonadal tumors.
Most patients had been treated according to the Brazilian GCTPro-
tocol-99 and received TIP – paclitaxel, ifosfamide and cisplatin as
second line chemotherapy. One patient was in the first remission
of a testicular tumor with trophoblastic component and multiple
brain and lung metastases; seven were in second remission; one
was in third remission and two had refractory disease with partial re-
sponse to therapy. All patients had a normal bone marrow aspirate
and biopsy prior to stem cell collection. Eight patients had periph-
eral blood stem cell harvest, one marrow, and one both, for a target
cell dose of 5 million CD34 cells/kg. All patients had febrile neutro-
penia (seven also had positive blood cultures), oral mucositis (all
needed IVmorphine) and diarrhea. One 3-year-old girl in second re-
mission had a CNS bleeding and died two months after HSCT. Five
patients had disease progression or relapse, three of them with ad-
vanced diseases. Five patients are alive in complete remission with
a median follow up of 6.8 years (2-8 years). In conclusion, GCT is
a rare indication of autologous HSCT in pediatrics (11/123 autolo-
gous transplants in 10 years). Despite acceptable results in adults
with refractory diseases, the best timing for autologous transplanta-
tion in pediatrics seems to be second remission. Carboplatin, etopo-
side and melphalan, the same regimen that has been used for many
years for stage 4 neuroblastoma, is associated with considerable tox-
icity but four of six evaluable patients with GCT in second remission
remain tumor-free more than six years after transplant.292
FLUDARABINE, BUSULFAN, AND ALEMTUZUMAB AS A REDUCEDTOXICITY
REGIMEN FOR CHILDREN WITH MARROW STEM CELL DEFECTS AND
MALIGNANCY IMPROVES ENGRAFTMENT AND GRAFT VERSUS HOST
DISEASE WITHOUT DELAYING IMMUNE RECONSTITUTION
Law, J.1, Cowan, M.J.1, Dvorak, C.C.1, Baxter-Lowe, L.A.3,
Musick, L.2, Hwang, J.4, Horn, B.1 1University of California San
Francisco, San Francisco, CA; 2University of California San Francisco,
San Francisco, CA; 3University of California San Francisco, San Fran-
cisco, CA; 4University of California San Francisco, San Francisco, CA
For many children with malignancies and MSCD, allogeneic he-
matopoietic cell transplant (HCT) provides the best chance of
cure. However, toxicity of conditioning and graft failure remain
challenges. We previously reported that busulfan, fludarabine and
rabbit ATG conditioning (total dose5 8mg/kg) resulted in less tox-
icity but no improvement in engraftment rates. Alemtuzumab has
been shown to enhance engraftment and reduce rates of GVHD in
myeloablative regimens. Thus, we prospectively evaluated targeted
IV busulfan, fludarabine and Alemtuzumab (total dose 5 1.5mg/
kg) in a Phase II study of children receiving closely matched related
or unrelatedHCT. Thirty-five children were enrolled: 5 with malig-
nancies and 30 withMSCD. Twelve donors were HLAmatched rel-
atives, 16 were fully HLA allele-matched unrelated donors and 7
were 9/10 HLA allele-matched unrelated donors. No patient had
more than a Grade 2 reaction to Alemtuzumab. The most common
toxicity (n 5 15) was Grade 3 mucositis. One patient had Grade 4
mucositis. Only 1 patient developed VOD (Grade 3). 11/15 CMV
seropositive patients had reactivation and 3/17 CMV seronegative
patients had primary CMV infection.None developedCMVdisease.
Thirty-one of 34 (88%) evaluable patients achieved durable engraft-
ment. Neutrophil recovery occurred at a median of 16 days (range
10-25). Three patients (2 mismatched at 1 antigen) with MSCD
failed to engraft from unrelated donor HCT and underwent subse-
quent transplants. One is alive and progression free. For those suc-
cessfully engrafted, the median time to CD4 . 200x10e6cells/L
and PHA . 50% was 6 months with a maximum of 9 months. At
1 year post transplant, 18/19 evaluable patients had 87%ormore do-
nor chimerism in whole blood, CD14/15+ and CD19+ subsets and
71% or more donor chimerism in the CD3+ subset. One patient
had only 55% whole blood donor chimerism at 1 year but ultimately
achieved 82%. Six patients developed acute Graft versus Host Dis-
ease (GVHD) of Grade 2-4 with only 1 patient progressing to
chronic GVHD. Seven patients had disease progression/relapse
with 1 dying from disease. Four patients died of Transplant Related
Mortality (11%). At a median follow up of 29 months (range 3-74),
the EFS was 60+/2 SE9% with an Overall Survival of 81+/
